Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis.
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 23 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 23 samples: 19 distinct titles, 2 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE254725_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1071573 and SRA study SRP487129. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 23 sample titles: 19 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8056597 RPMI_DMSO_05-05
- GSM8056598 RPMI_DMSO_10-05
- GSM8056599 RPMI_DMSO_25-01
- GSM8056600 RPMI_MS1943_05-05
- GSM8056601 RPMI_MS1943_10-05
- GSM8056602 RPMI_MS1943_25-01
- GSM8056603 RPMI_Romi_+_MS_05-05
- GSM8056604 RPMI_Romi_+_MS_10-05
- GSM8056605 RPMI_Romi_+_MS_25-01
- GSM8056606 RPMI_Romi_05-05
- GSM8056607 RPMI_Romi_10-05
- GSM8056608 RPMI_Romi_25-01
- GSM8056609 RPMI-DMSO-72h-1
- GSM8056610 RPMI-DMSO-72h-2
- GSM8056611 RPMI-DMSO-72h-3
- GSM8056612 RPMI-Taz5-72h-1
- GSM8056613 RPMI-Taz5-72h-2
- GSM8056614 RPMI-Taz5-72h-3
- GSM8056703 RPMI-DMSO-H3K27ac
- GSM8056704 RPMI-MS1943-H3K27ac
- GSM8056705 RPMI-Romidepsin-H3K27ac
- GSM8056706 RPMI-RomiMS-H3K27ac
- GSM8056707 RPMI-input
- GSE254719 Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis. [RNA-Seq] 18 samples shares ezh2, hematological, deacetylases, malignancies, deregulation, ferroptosis, targeting, promotes
- GSE277818 Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies 12 samples shares hematological, malignancies, targeting
- GSE176493 Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma 252 samples shares ezh2, targeting
- GSE324154 Therapy Induced Senescence Promotes Immunogenicity in Acute Myeloid Leukemia through Reduced EZH2 Activity 22 samples shares ezh2, promotes
- GSE302321 Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers - ChIP-seq data from genetic disruption of EZH2 41 samples shares ezh2, targeting
- GSE296858 Crosstalk between EZH2 and m6A RNA methylation promotes prostate cancer progression through modulating an m6A autoregulation pathway 30 samples shares ezh2, promotes
- GSE272538 A novel association of EZH2 and E2F1 promotes breast cancer cell proliferation through chromatin remodeling [RNA-Seq] 18 samples shares ezh2, promotes
- GSE229736 Therapy Induced Senescence Promotes Immunogenicity in Acute Myeloid Leukemia through Reduced EZH2 Activity (RNA-seq AraC) 12 samples shares ezh2, promotes
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.